- Drug and Therapeutics Bulletin
- 1Drug and Therapeutics Bulletin Editorial Office, BMA House, London WC1H 9JR
- dtb{at}bmjgroup.com
Summary points
Gastro-oesophageal reflux is common in infants, particularly preterm babies, younger infants, and those with neurodevelopmental disorders
Reflux is usually self limiting and without complications. Occasionally, it is associated with troublesome symptoms or complications (such as respiratory disorders or suspected oesophagitis), when it is known as gastro-oesophageal reflux disease (GORD)
Parental education and reassurance, changes in feeds, thickening of fluids, or an alginate combination should be tried first for managing GORD. Infants whose symptoms are unresponsive, or those with complications, should be referred to specialist paediatric services for investigation
An H2 receptor antagonist to reduce acid secretion may be needed to control the condition, but there is little evidence to support such therapy. Ranitidine, which is licensed for use from 6 months of age, is now recommended by the BNF for Children as the most suitable such drug for infants
If an H2 receptor antagonist is unsuccessful, the next step is treatment with omeprazole (unlicensed in infants) or surgery
No other drugs are licensed or recommended for GORD in infants
Transient, inappropriate relaxation of the lower oesophageal sphincter may permit contents of the stomach to pass into the oesophagus (gastro-oesophageal reflux).1 This usually presents as regurgitation or vomiting and is common in infants, when it is usually mild and self limiting, and requires no specific treatment.1 Gastro-oesophageal reflux disease (GORD) in infants describes reflux of gastric contents that causes troublesome symptoms or complications.2 GORD is sometimes wrongly diagnosed in healthy infants with troublesome but harmless symptoms of “physiological” gastro-oesophageal reflux.3 This has led to increasing, potentially inappropriate, use of acid reducing drugs.3 4 Furthermore, few of the drugs used to treat infants with GORD are licensed for this use, a situation that DTB criticised 12 years ago.1 Here we consider GORD in infancy …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012